Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes

Journal of Virology

Volumn 86, Issue 2, 2012, Pages 930-946

  De Silva, Thushan I ^a,b,c   Aasa Chapman, Marlén ^b   Cotten, Matthew ^a,h   Hué, Stéphane ^b   Robinson, James ^d   Bibollet Ruche, Frederic ^e   Sarge Njie, Ramu ^a   Berry, Neil ^f   Jaye, Assan ^a   Aaby, Peter ^g   Whittle, Hilton ^a   Rowland Jones, Sarah ^c   Weiss, Robin ^b  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^g Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Guinea-Bissau)

^h WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLYCOSYLATION; GUINEA-BISSAU; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; IC 50; MALE; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RURAL AREA; SEQUENCE ANALYSIS; VIRUS ENVELOPE; VIRUS NEUTRALIZATION;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; CELL LINE; COHORT STUDIES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; SEQUENCE ALIGNMENT;

HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 84856907465     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06126-11     Document Type: Article

References (81)

1. Aasa-Chapman MM, Aubin K, Williams I, McKnight A. 2006. Primary CCR5 only using HIV-1 isolates does not accurately represent the in vivo replicating quasi-species. Virology 351:489-496.
2. Aasa-Chapman MM, et al. 2011. In vivo emergence of HIV-1 highly sensitive to neutralizing antibodies. PLoS One 6:e23961.
3. Aasa-Chapman MM, et al. 2005. Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J. Virol. 79:2823-2830.
4. Aasa-Chapman MM, Seymour CR, Williams I, McKnight A. 2006. Novel envelope determinants for CCR3 use by human immunodeficiency virus. J. Virol. 80:10884-10889.
5. Abecasis AB, et al. 2010. Comparative performance of the REGA subtyping tool version 2 versus version 1. Infect. Genet. Evol. 10:380-385.
6. Alter G, Moody MA. 2010. The humoral response to HIV-1: new insights, renewed focus. J. Infect. Dis. 20(Suppl 2):S315-S322.
7. Arien KK, et al. 2005. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J. Virol. 79:8979-8990.
8. Ariyoshi K, et al. 1996. A community-based study of human immunodeficiency virus type 2 provirus load in rural village in West Africa. J. Infect. Dis. 173:245-248.
9. Bailey JR, et al. 2006. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J. Virol. 80:4758-4770.
10. Barroso H, et al. 2011. Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection. PLoS One 6:e14548.
11. Barroso H, Taveira N. 2005. Evidence for negative selective pressure in HIV-2 evolution in vivo. Infect. Genet. Evol. 5:239-246.
12. Berry N, et al. 1998. Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J. Hum. Virol. 1:457-468.
13. Berry N, et al. 2002. Low level viremia and high CD4% predict normal survival in a cohort of HIV type-2-infected villagers. AIDS Res. Hum. Retroviruses 18:1167-1173.
14. Bjorling E, et al. 1993. Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology 193:528-530.
15. Blaak H, van der Ende ME, Boers PH, Schuitemaker H, Osterhaus AD. 2006. In vitro replication capacity of HIV-2 variants from long-term aviremic individuals. Virology 353:144-154.
16. Blish CA, Blay WM, Haigwood NL, Overbaugh J. 2007. Transmission of HIV-1 in the face of neutralizing antibodies. Curr. HIV Res. 5:578-587.
17. Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H. 2008. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J. Virol. 82:7932-7941.
18. Calado M, et al. 2010. Coreceptor usage by HIV-1 and HIV-2 primary isolates: the relevance of CCR8 chemokine receptor as an alternative coreceptor. Virology 408:174-182.
19. Carlson JM, Brumme ZL. 2008. HIV evolution in response to HLArestricted CTL selection pressures: a population-based perspective. Microbes Infect. 10:455-461.
20. Clapham PR, McKnight A, Weiss RA. 1992. Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4. J. Virol. 66:3531-3537.
21. da Silva ZJ, et al. 2008. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing? AIDS 22:1195-1202.
22. Davis KL, et al. 2009. Human immunodeficiency virus type 2 (HIV-2)/ HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J. Virol. 83:1240-1259.
23. Decker JM, et al. 2005. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 201:1407-1419.
24. Deeks SG, et al. 2006. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J. Virol. 80: 6155-6164.
25. Delport W, et al. 2010. CodonTest: modeling amino acid substitution preferences in coding sequences. PLoS Comput. Biol. 6:e1000885.
26. de Silva TI, Cotten M, Rowland-Jones SL. 2008. HIV-2: the forgotten AIDS virus. Trends Microbiol. 16:588-595.
27. Duvall MG, et al. 2006. Maintenance of HIV-specific CD4+T cell help distinguishes HIV-2 from HIV-1 infection. J. Immunol. 176:6973-6981.
28. Fenyo EM, et al. 2009. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One 4:e4505.
29. Frost SD, et al. 2005. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl. Acad. Sci. U. S. A. 102:18514-18519.
30. Gao F, et al. 1994. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J. Virol. 68:7433-7447.
31. Gray ES, et al. 2007. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J. Virol. 81: 6187-6196.
32. Guyader M, et al. 1987. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature 326:662-669.
33. Hodges-Mameletzis I, De Bree GJ, Rowland-Jones SL. 2011. An underestimated lentivirus model: what can HIV-2 research contribute to the development of an effective HIV-1 vaccine? Expert Rev. Anti Infect. Ther. 9:195-206.
34. Jordan MR, et al. 2010. Comparison of standard PCR/cloning to single genome sequencing for analysis of HIV-1 populations. J. Virol. Methods 168:114-120.
35. Kong R, et al. 2009. Epitope mapping of neutralizing antibody 1.7A on the HIV-2 gp160 glycoprotein, abstr 332. Abstr. 16th Conf. Retroviruses Opportunistic Infections, Montreal, Quebec, Canada.
36. Kong R, et al. 2012. Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection. J. Virol. 86:947-960.
37. Korber BT, et al. 1994. Genetic differences between blood- and brainderived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J. Virol. 68:7467-7481.
38. Kosakovsky Pond SL, Frost SD. 2005. Not so different after all: a comparison of methods for detecting amino acid sites under selection. Mol. Biol. Evol. 22:1208-1222.
39. Kosakovsky Pond SL, Posada D, Gravenor MB, Woelk CH, Frost SD. 2006. Automated phylogenetic detection of recombination using a genetic algorithm. Mol. Biol. Evol. 23:1891-1901.
40. Larkin MA, et al. 2007. Clustal W and Clustal X version 2.0. Bioinformatics 23:2947-2948.
41. Leligdowicz A, et al. 2010. Highly avid, oligoclonal, early-differentiated antigen-specific CD8(+)T-cells in chronic HIV-2 infection. Eur. J. Immunol. 40:1963-1972.
42. Leligdowicz A, et al. 2007. Robust Gag-specific T cell responses characterize viremia control in HIV-2 infection. J. Clin. Invest. 117:3067-3074.
43. Le Tortorec A, Neil SJ. 2009. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J. Virol. 83:11966-11978.
44. Louder MK, et al. 2005. HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology 339:226-238.
45. MacNeil A, et al. 2007. Long-term intrapatient viral evolution during HIV-2 infection. J. Infect. Dis. 195:726-733.
46. Mahalanabis M, et al. 2009. Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J. Virol. 83:662-672.
47. Marcelino JM, et al. 2010. Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy. J. Virol. 84:12429-12436.
48. Martin N, et al. 2010. Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J. Virol. 84:3516-3527.
49. McMichael AJ, Phillips RE. 1997. Escape of human immunodeficiency virus from immune control. Annu. Rev. Immunol. 15:271-296.
50. Meyerhans A, Vartanian JP, Wain-Hobson S. 1990. DNA recombination during PCR. Nucleic Acids Res. 18:1687-1691.
51. Montefiori DC, Hill TS, Vo HT, Walker BD, Rosenberg ES. 2001. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J. Virol. 75:10200-10207.
52. Moore PL, Gray ES, Morris L. 2009. Specificity of the autologous neutralizing antibody response. Curr. Opin. HIV AIDS 4:358-363.
53. Moore PL, et al. 2009. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 5:e1000598.
54. Onyango CO, et al. 2010. HIV-2 capsids distinguish high and low virus load patients in a West African community cohort. Vaccine 28(Suppl 2):B60-B67.
55. Piantadosi A, et al. 2009. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J. Virol. 83:10269-10274.
56. Pinter A, et al. 2004. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J. Virol. 78:5205-5215.
57. Pond SL, Frost SD. 2005. Datamonkey: rapid detection of selective pressure on individual sites of codon alignments. Bioinformatics 21: 2531-2533.
58. Pond SL, et al. 2006. Adaptation to different human populations by HIV-1 revealed by codon-based analyses. PLoS Comput. Biol. 2:e62.
59. Popper SJ, et al. 2000. Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo. J. Virol. 74:1554-1557.
60. Popper SJ, et al. 1999. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J. Infect. Dis. 180:1116-1121.
61. Posada D. 2006. ModelTest server: a web-based tool for the statistical selection of models of nucleotide substitution online. Nucleic Acids Res. 34:W700-W703.
62. Richman DD, Wrin T, Little SJ, Petropoulos CJ. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 100:4144-4149.
63. Rodriguez SK, et al. 2007. Comparison of heterologous neutralizing antibody responses between human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections. J. Virol. 81: 5331-5338.
64. Rong R, et al. 2007. Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J. Virol. 81:1350-1359.
65. Rong R, et al. 2009. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog. 5:e1000594.
66. Sagar M, Wu X, Lee S, Overbaugh J. 2006. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 80:9586-9598.
67. Salazar-Gonzalez JF, et al. 2008. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by singlegenome amplification and sequencing. J. Virol. 82:3952-3970.
68. Schim van der Loeff MF, et al. 2010. Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology 7:46.
69. Schramm B, et al. 2000. Cytopathicity of human immunodeficiency virus type 2 (HIV-2) in human lymphoid tissue is coreceptor dependent and comparable to that of HIV-1. J. Virol. 74:9594-9600.
70. Seaman MS, et al. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84: 1439-1452.
71. Shi Y, et al. 2005. Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. J. Gen. Virol. 86:3385-3396.
72. Skrabal K, et al. 2005. Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity. J. Virol. 79:11848-11857.
73. Soda Y, et al. 1999. Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line. Biochem. Biophys. Res. Commun. 258:313-321.
74. Thomas ER, Shotton C, Weiss RA, Clapham PR, McKnight A. 2003. CD4-dependent and CD4-independent HIV-2: consequences for neutralization. AIDS 17:291-300.
75. van der Kuyl AC, Cornelissen M. 2007. Identifying HIV-1 dual infections. Retrovirology 4:67.
76. van Tienen C, et al. 2010. Two distinct epidemics: the rise of HIV-1 and decline of HIV-2 infection between 1990 and 2007 in rural Guinea-Bissau. J. Acquir. Immune Defic. Syndr. 53:640-647.
77. Wei X, et al. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
78. Wei X, et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312.
79. Wren L, Kent SJ. 2011. HIV vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity. Hum. Vaccin 7:466-473.
80. Wu X, et al. 2006. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J. Virol. 80: 835-844.
81. Zhang M, et al. 2004. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14: 1229-1246.